Semax research by brain region — Peptide Friend

Frontal-cortex NGF

In the 2007 Semax experiment in male Wistar rats, the researchers measured gene expression across several brain regions. BDNF and NGF mRNA rose in the hippocampus; BDNF rose in the brainstem and cerebellum; NGF mRNA fell in the frontal cortex. Messenger RNA, or mRNA, is the cell’s working copy of a gene’s instructions. Here it was a measure of gene activity.

I’m drawn to Semax’s map of increases and decreases, before any general claim about mental sharpness. The animals received Semax, the regions responded differently, and the experiment measured molecular changes. It gives us a much more particular question: why this pattern, in these tissues?

Basal-forebrain BDNF protein

A 2006 rat study also measured BDNF protein, which rose in the basal forebrain at 3 hours, while the cerebellum did not show that protein increase. The study also described specific, reversible, calcium-dependent binding to brain membranes, with a dissociation constant of about 2.4 nM.

The difference between protein and gene-expression measurements matters here. A BDNF mRNA finding in the cerebellum in one experiment and a BDNF protein finding in another region in another experiment answer distinct questions. Semax’s regional specificity impresses me. A general promise of improved cognition would lose it.

The ACTH fragment

Semax is a synthetic peptide, a short chain of amino acids. Its seven-amino-acid sequence combines the ACTH(4-7) fragment with a Pro-Gly-Pro tail intended to slow breakdown. It lacks the cortisol-releasing activity of full-length ACTH. The neurotrophin study examines this ACTH-derived molecule.

Semax has prescription registrations in Russia and Ukraine for ischemic stroke, transient ischemic attack, cognitive impairment and optic-nerve disease. It has no FDA or EMA drug approval. Research-labelled material remains in circulation; U.S. prescription decisions require a licensed clinician’s assessment of the individual case.

Injured brain and spinal cord

The injury experiments deserve their own conversation. In rats with focal cortical ischemia, Semax reduced the volume of damaged cortex and preserved a learned passive-avoidance response. Ischemia means an inadequate blood supply. Those animals had an experimental brain injury.

A genome-wide analysis in rats with cerebral ischemia found that immune-system genes accounted for more than half of the affected genes, alongside changes in vascular-system genes. That finding broadens the biological picture beyond growth factors.

Then the 2025 study in female mice with spinal-cord injury reported improved functional recovery and reduced pyroptosis, an inflammatory form of cell death. The proposed mechanism involved the mu-opioid-receptor gene Oprm1 and the USP18/FTO pathway. I’d put recovery after a defined injury at the center of any discussion of that paper. An ordinary afternoon of difficult work presents a very different question.

Semax safety and focus reports

People in peptide and nootropic communities describe clarity, sustained focus, easier word recall and a lift in mood. Others describe an effect too subtle to judge, or no useful effect. Reports also include tiredness, irritability, headache and nasal irritation. These are anecdotal accounts rather than clinical evidence, and they give us no reliable rate of benefit or harm.

The unresolved issue for me is repeated exposure in a healthy human brain. The regional neurotrophin findings and the immune-gene changes come largely from rodents; long-term safety in healthy people remains uncharacterized. Most of the clinical record comes from Russian and Ukrainian institutions, and published Western randomized controlled trials are absent. Interactions with stimulants, serotonergic drugs and opioid-active compounds also remain insufficiently studied.

The Selank page takes up another interaction problem. For sleep, the DSIP record has a different history altogether.